# Daily Prospects - February 26, 2026

**Generated:** 9:14 AM EST
**Total Prospects:** 14
**High Priority (80+):** 4
**Total Potential Fees:** $47,000 - $65,000

---

## üî• HIGH PRIORITY (Score 80+)

### 1. Handl Health | Score: 92
**Vertical:** Technology/SaaS (Healthcare Intelligence)
**Location:** Culver City, CA
**Fee Potential:** $5,000 - $7,500 (10-20% ACV)

**Buying Signals:**
- ‚úÖ $14.2M Series A announced TODAY (Feb 26, 2026)
- ‚úÖ Led by Arthur Ventures
- ‚úÖ 300% revenue growth in last 12 months
- ‚úÖ Cedars-Sinai Accelerator graduate (2023)
- ‚úÖ Expanding team for platform rollout
- ‚úÖ B2B focus: serves insurance brokers & TPAs

**Score Breakdown:**
- Intent Signals: 38/40 (same-day funding announcement)
- Vertical Fee: 28/30 (SaaS, high ACV potential)
- Company Size: 18/20 (growth stage, 50-100 employees est.)
- Signal Specificity: 8/10 (very recent, detailed)

**Outreach Priority:** IMMEDIATE - contact within 24 hours

---

### 2. Newo | Score: 87
**Vertical:** Technology/SaaS (AI)
**Location:** San Francisco, CA
**Fee Potential:** $5,000 - $7,500

**Buying Signals:**
- ‚úÖ $25M Series A (announced Feb 2026)
- ‚úÖ AI innovator - likely expanding tech stack
- ‚úÖ SF-based (high-cost market = needs efficiency)
- ‚úÖ Post-funding hiring phase

**Score Breakdown:**
- Intent Signals: 35/40 (recent funding)
- Vertical Fee: 28/30 (SaaS/AI)
- Company Size: 17/20 (Series A = growth stage)
- Signal Specificity: 7/10 (recent but limited details)

**Outreach Priority:** HIGH - contact within 48 hours

---

### 3. Wootz.work | Score: 84
**Vertical:** Manufacturing (B2B Equipment Marketplace)
**Location:** Delhi, India (US expansion likely)
**Fee Potential:** $1,000 - $3,000

**Buying Signals:**
- ‚úÖ $6.6M Series A (announced Feb 25, 2026)
- ‚úÖ Led by Z47, Nexus Venture Partners
- ‚úÖ Expanding engineering footprint
- ‚úÖ Deepening manufacturing control systems
- ‚úÖ Previous seed: $3.5M (Aug 2023)

**Score Breakdown:**
- Intent Signals: 34/40 (yesterday's announcement)
- Vertical Fee: 20/30 (manufacturing = lower fee)
- Company Size: 18/20 (rapid growth)
- Signal Specificity: 8/10 (detailed expansion plans)

**Outreach Priority:** HIGH - manufacturing control systems = consulting opportunity

---

### 4. Grotto AI | Score: 81
**Vertical:** Commercial Real Estate (Multifamily)
**Location:** Unknown (likely US)
**Fee Potential:** $3,000 - $10,000

**Buying Signals:**
- ‚úÖ $10M Seed from ICONIQ Capital
- ‚úÖ AI-powered real-time coaching for multifamily leasing
- ‚úÖ Real estate tech = high-value consulting
- ‚úÖ Improving conversion rates = revenue focus

**Score Breakdown:**
- Intent Signals: 32/40 (seed funding, growth phase)
- Vertical Fee: 26/30 (CRE tech = high fees)
- Company Size: 15/20 (early stage but funded)
- Signal Specificity: 8/10 (clear value prop)

**Outreach Priority:** HIGH - real estate vertical, premium fees

---

## üìä MEDIUM PRIORITY (Score 60-79)

### 5. BreezeBio | Score: 76
**Vertical:** B2B Professional Services (Biotech/Pharma)
**Location:** Unknown
**Fee Potential:** $5,000 - $7,500

**Buying Signals:**
- ‚úÖ $60M Series B
- ‚úÖ Pivot from collaborations to own therapy pipeline
- ‚úÖ Nanoparticle delivery system development
- ‚úÖ Autoimmune/cancer focus

**Score Breakdown:**
- Intent Signals: 32/40 (large funding, pivot)
- Vertical Fee: 25/30 (biotech consulting)
- Company Size: 14/20 (Series B = established)
- Signal Specificity: 5/10 (less specific on needs)

---

### 6. Slate (Stealth Biotech) | Score: 74
**Vertical:** B2B Professional Services (Biotech)
**Location:** Unknown
**Fee Potential:** $5,000 - $7,500

**Buying Signals:**
- ‚úÖ $130M exit from stealth
- ‚úÖ Cardiovascular RNAi medicines
- ‚úÖ Clinical trials starting mid-2026
- ‚úÖ Building out infrastructure

**Score Breakdown:**
- Intent Signals: 30/40 (major funding, infrastructure build)
- Vertical Fee: 25/30 (biotech)
- Company Size: 15/20 (well-funded)
- Signal Specificity: 4/10 (stealth = limited info)

---

### 7. Poplar Therapeutics | Score: 71
**Vertical:** B2B Professional Services (Biotech/Immunology)
**Location:** Unknown (formerly Phylaxis Bioscience)
**Fee Potential:** $5,000 - $7,500

**Buying Signals:**
- ‚úÖ $50M Series A (Jan 2026)
- ‚úÖ Anti-IgE therapies for food allergy
- ‚úÖ Advancing pipeline
- ‚úÖ Investors: SR One, Vida Ventures, Platanus

**Score Breakdown:**
- Intent Signals: 28/40 (funding, pipeline advancement)
- Vertical Fee: 25/30 (biotech)
- Company Size: 13/20 (Series A stage)
- Signal Specificity: 5/10 (standard biotech profile)

---

### 8. Hook | Score: 68
**Vertical:** Technology/SaaS (Music/AI Platform)
**Location:** Unknown
**Fee Potential:** $5,000 (10-20% ACV)

**Buying Signals:**
- ‚úÖ $10M Series A from Waverley Capital
- ‚úÖ Artist-first social platform
- ‚úÖ AI-powered music creation/remixing
- ‚úÖ Platform expansion phase

**Score Breakdown:**
- Intent Signals: 27/40 (funding, platform growth)
- Vertical Fee: 22/30 (SaaS but consumer-adjacent)
- Company Size: 12/20 (Series A)
- Signal Specificity: 7/10 (clear model)

---

### 9. Leadbay | Score: 65
**Vertical:** Technology/SaaS (B2B Sales AI)
**Location:** Unknown
**Fee Potential:** $5,000 (10-20% ACV)

**Buying Signals:**
- ‚úÖ $500K funding (early stage)
- ‚úÖ AI models for B2B sales lead generation
- ‚úÖ Active in market
- ‚úÖ 2 investors onboard

**Score Breakdown:**
- Intent Signals: 24/40 (smaller funding)
- Vertical Fee: 24/30 (B2B SaaS)
- Company Size: 10/20 (early stage)
- Signal Specificity: 7/10 (clear positioning)

---

## üìã STANDARD PRIORITY (Score 40-59)

### 10. COR-2003 Program Company | Score: 58
**Vertical:** B2B Professional Services (Cardiovascular)
**Location:** Unknown
**Fee Potential:** $5,000 - $7,500

**Buying Signals:**
- ‚úÖ Clinical trial starting mid-2026
- ‚úÖ Angiotensinogen-targeting therapy
- ‚úÖ Preventative RNAi medicines
- ‚ö†Ô∏è Limited company details

**Score Breakdown:**
- Intent Signals: 22/40 (clinical trial = hiring needs)
- Vertical Fee: 24/30 (biotech/pharma)
- Company Size: 8/20 (unknown)
- Signal Specificity: 4/10 (program-level info only)

---

### 11. Altesa | Score: 55
**Vertical:** B2B Professional Services (Biotech)
**Location:** Unknown
**Fee Potential:** $5,000 - $7,500

**Buying Signals:**
- ‚úÖ $75M Series B
- ‚úÖ Active fundraising (tracked)
- ‚ö†Ô∏è Limited operational details

**Score Breakdown:**
- Intent Signals: 24/40 (well-funded)
- Vertical Fee: 22/30 (biotech)
- Company Size: 6/20 (limited info)
- Signal Specificity: 3/10 (funding only)

---

### 12. Ember Lifesciences | Score: 52
**Vertical:** B2B Professional Services (Life Sciences)
**Location:** Unknown
**Fee Potential:** $5,000 - $7,500

**Buying Signals:**
- ‚úÖ $16.5M Series A (Jan 2026)
- ‚úÖ Life sciences focus
- ‚ö†Ô∏è Minimal public information

**Score Breakdown:**
- Intent Signals: 22/40 (funding)
- Vertical Fee: 22/30 (life sciences)
- Company Size: 5/20 (limited info)
- Signal Specificity: 3/10 (minimal details)

---

### 13. Tebra | Score: 48
**Vertical:** Technology/SaaS (Healthcare)
**Location:** Unknown
**Fee Potential:** $5,000 - $7,500

**Buying Signals:**
- ‚úÖ $250M funding (major raise)
- ‚úÖ AI healthcare focus
- ‚úÖ Large capital deployment phase
- ‚ö†Ô∏è Mature company (less consulting need)

**Score Breakdown:**
- Intent Signals: 20/40 (funded but mature)
- Vertical Fee: 20/30 (SaaS healthcare)
- Company Size: 5/20 (likely established)
- Signal Specificity: 3/10 (limited context)

---

### 14. Cedars-Sinai Accelerator Cohort 2024-2025 | Score: 45
**Vertical:** Multiple (Healthcare Startups)
**Location:** Los Angeles, CA
**Fee Potential:** $3,000 - $5,000 (varies)

**Buying Signals:**
- ‚úÖ Accelerator graduates
- ‚úÖ Healthcare delivery/patient care focus
- ‚úÖ Grant + mentorship received
- ‚úÖ Building infrastructure

**Score Breakdown:**
- Intent Signals: 18/40 (accelerator = early)
- Vertical Fee: 18/30 (healthcare mix)
- Company Size: 5/20 (early stage)
- Signal Specificity: 4/10 (cohort-level)

---

## Summary Statistics

| Metric | Value |
|--------|-------|
| Total Prospects | 14 |
| High Priority (80+) | 4 |
| Medium Priority (60-79) | 5 |
| Standard Priority (40-59) | 5 |
| **Total Potential Fees** | **$47,000 - $65,000** |

## Vertical Breakdown

| Vertical | Count | Avg Score |
|----------|-------|-----------|
| Technology/SaaS | 5 | 71.4 |
| B2B Professional Services (Biotech) | 6 | 64.8 |
| Manufacturing | 1 | 84 |
| Commercial Real Estate | 1 | 81 |

## Top 3 Prospects for Immediate Outreach

1. **Handl Health** (92) - $14.2M Series A TODAY, 300% growth, healthcare SaaS
2. **Newo** (87) - $25M Series A, AI innovator, SF-based
3. **Wootz.work** (84) - $6.6M Series A yesterday, manufacturing expansion

---

*Generated by B2B Referral Engine - Prospect Identification Module*
*Next run: February 27, 2026*
